Xu Jiuzhen, chairman and ultimate controller of Shanghai Aladdin Biochemical Technology Co., Ltd. (stock code 688179), has filed a plan to sell up to 3 million shares — roughly 0.9% of the company’s issued capital — through block trades over a three‑month window beginning 15 trading days after the announcement. At Aladdin’s prevailing price this winter, the maximum proceeds would be about ¥50 million, a modest sum relative to the company’s ¥57.3 billion market capitalisation but significant as a signal from the controlling shareholder.
Aladdin, long billed in Chinese markets as a leading maker of scientific reagents, released 2025 preliminary results showing a 28.7% rise in revenue to ¥686 million and a modest 4.8% increase in net profit attributable to the parent company. Profit growth accelerated in the second half of the year, with fourth‑quarter net profit up 74% year‑on‑year, which underscores that the planned sale comes amid improving operational performance rather than a collapse in fundamentals.
The planned reduction follows earlier disposals by the company’s employee shareholding platform, Jingzhen Culture, which completed a 2.4 million‑share sale via regular trading. Corporate filings also show a reorganisation of shares held by Jingzhen’s partners after the platform’s dissolution and highlight close family and business ties: Xu and his wife hold full ownership of a related supply‑chain firm, and Xu’s spouse is an executive partner in Jingzhen’s affairs. These ownership structures are common in China but complicate assessments of whether such sales reflect personal liquidity needs or a strategic recalibration.
From a market‑micro perspective, the seller plans to use block trades, a route that typically reduces market impact and signalling compared with open market sales. The maximum disposal represents less than 1% of the company’s outstanding stock and should not materially affect long‑term valuation if investors focus on earnings momentum and the growing domestic demand for research reagents. Nonetheless, repeated insider sell‑downs can erode investor confidence in governance and management’s alignment with minority shareholders.
For the broader reagents sector, Aladdin’s performance matters as an indicator of steady demand for laboratory consumables in China’s research and biotech industries. The company benefits from scale in reagent production and distribution, but it faces intense competition, pricing pressure, and the need to sustain R&D investment to protect margins. How management deploys capital — including whether insiders are converting holdings into personal cash rather than funding growth initiatives — will shape investor perceptions going forward.
In short, this is a liquidity move by a founder at a time of improving operational metrics. Economically it is small; symbolically it is meaningful. Investors will be watching both the transaction mechanics and whether further insider reductions follow, as those developments will speak to confidence in the company’s medium‑term strategy and governance.